All about Pulse Field Ablation

Atrial fibrillation (AF), is the commonest cardiac arrhythmia, affects millions worldwide and increases the risk of stroke, heart failure, and reduces life expectancy. Traditional treatments include medications and a curative procedure called catheter ablation using thermal energy—either radiofrequency (heat) or cryoablation (cold)—to isolate the pulmonary veins and prevent the electrical signals that provoke AF. However, these methods can unintentionally damage nearby tissues such as the oesophagus or phrenic nerve leading to serious complications.

Pulse Field Ablation (PFA) is an emerging, non-thermal ablation technology that is a safer alternative. Also known as electroporation, PFA uses short, high-voltage electrical pulses to create microscopic pores in the cell membranes of cardiac tissue, leading to cell death and delivery near the pulmonary veins can achieve effective pulmonary vein isolation. Because PFA preferentially affects myocardial cells while sparing surrounding non-cardiac structures, it significantly reduces the risk of collateral damage. There have been no cases of oesophageal injury from PFA worldwide and phrenic nerve injury (well recognised with cryoablation) is vanishingly rare with PFA.

Recent clinical studies have demonstrated the safety and efficacy of PFA in treating both paroxysmal and persistent AF. Patients typically experience shorter procedure times, faster recovery, and fewer complications compared to traditional ablation. Furthermore, early results suggest that PFA may offer more durable lesion formation, potentially improving long-term outcomes.

Regulatory bodies in Europe have already approved many PFA systems, and many centres use it routinely in the U.S. it is rapidly being adopted throughout the UK as the primary method of performing AF ablation and is revolutionising AF management by making catheter ablation safer, faster, quicker to recover from and more accessible.

As technology advances and more data becomes available, Pulse Field Ablation holds great promise in redefining the standard of care for atrial fibrillation and other cardiac arrhythmias. Cardiac electrophysiologists are excited at now offering this state of the art treatment for patients.